|
*停權中*
|
引用:
|
作者IWB
Pfizer不是11月才進入三期. 官網寫了是7/27開始第三期測試
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints ( https://www.pfizer.com/news/press-r...ovid-19-vaccine)
原文
"The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. "
Google翻譯
"BNT162b2 的 3 期臨床試驗於 7 月 27 日開始，迄今已招募了 43,661 名參與者，截至 2020 年 11 月 13 日，其中 41,135 人已接受第二劑候選疫苗。 " |
去年7/27新聞稿是寫 2/3期。
至於為什麼？有什麼不一樣？要問輝瑞。
實際在美國的臨床實驗，
本案正式名稱寫1/ 2 /3期，
開始於2020/4/29，
預計主要結束日：2021/11/2
預計研究結束日：2023/5/2
三期應該還沒結束，還要一段時間……
https://clinicaltrials.gov/ct2/show...8，#eligibility
引用:
Study Type :Interventional (Clinical Trial)
Estimated Enrollment :43998 participants
Allocation:Randomized
Intervention Model:Parallel Assignment
Masking:Triple (Participant, Care Provider, Investigator)
Primary Purpose:Prevention
Official Title:A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Actual Study Start Date :April 29, 2020
Estimated Primary Completion Date :November 2, 2021
Estimated Study Completion Date :May 2, 2023
|
|